Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Dendrobium huoshanense* is a rare medicinal orchid endemic to Huoshan County, China, widely utilized in Traditional Chinese Medicine (TCM) for its immunomodulatory, anti-inflammatory, and gastroprotective properties. Its primary bioactive constituents are polysaccharides (DHPs), alongside flavonoids and alkaloids. In clinical settings, it is being investigated as an adjuvant therapy in neoadjuvant chemoradiation for locally advanced rectal cancer to enhance immune function and alleviate treatment-induced symptoms like radiation proctitis. Preclinical studies suggest broader therapeutic potential in metabolic disorders (hyperuricemia, type 1 diabetes), neurodegenerative diseases (Alzheimer's and Parkinson's), and inflammatory bowel diseases (ulcerative colitis) through mechanisms involving the regulation of the HPA axis, antioxidant pathways (Nrf2/HO-1), and the gut-microbiota-GLP-1 axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dendrobium huoshanense.